novo nordisk semaglutide clinical trials New Wegovy trial finds surprising benefits that go way beyond weight loss A second helping of weight-loss
Description
New England Journal of Medicine, 384 (11), 9891002.
Las soluciones turbias o con partculas son motivo de descarte
The rationale is that even sub-therapeutic doses activate the GLP-1 and GIP receptors enough to produce noticeable appetite modulation without the gastrointestinal side effects that trouble many users during standard initiation
10.1038/nature05354 15 BouretS
